# Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

Source: https://onco.cc/trials/nct02260817/  
OnCo record `nct02260817` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Choline C-11 in Prostate cancer, run by Global Isotopes, LLC d/b/a Zevacor Molecular, completed.

## Summary

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer is a phase 3 interventional study registered as NCT02260817 by Global Isotopes, LLC d/b/a Zevacor Molecular, with 109 participants recorded, started 2014-10 and reaching its primary completion in 2016-06. Interventions recorded: 11C-choline Injection. Conditions recorded: Metastatic Prostate Cancer.

Linked to the drug Choline C-11 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02260817
- Phase: 3
- Setting: Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
- Sponsor: Global Isotopes, LLC d/b/a Zevacor Molecular
- Enrolled: 109

## Sources

- ClinicalTrials.gov NCT02260817: https://clinicaltrials.gov/study/NCT02260817

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Choline C-11](https://onco.cc/drugs/choline-c11/)

---
JSON: https://onco.cc/api/v1/entities/nct02260817.json